ActiQs / Forskning

PUBLIKATIONSREGISTRET

Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för pergolide mesylate. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

20 träffar

Bibliografisk träff 2019-02-08

Pharmacokinetics and pharmacodynamics of pergolide mesylate after oral administration in horses with pituitary pars intermedia dysfunction.

Rendle DI, Doran G, Ireland J, Edwards S.

Domest Anim Endocrinol · research support, non-u.s. gov't; journal article; clinical trial, veterinary · DOI 10.1016/j.domaniend.2019.01.008

Bibliografisk träff 2016-06-15

Pharmacokinetic and pharmacodynamic properties of pergolide mesylate following long-term administration to horses with pituitary pars intermedia dysfunction.

McFarlane D, Banse H, Knych HK, Maxwell LK.

J Vet Pharmacol Ther · clinical trial; journal article · DOI 10.1111/jvp.12339

Bibliografisk träff 2013-11-13

A pharmacological network for lifespan extension in Caenorhabditis elegans.

Ye X, Linton JM, Schork NJ, Buck LB, Petrascheck M.

Aging Cell · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1111/acel.12163

Bibliografisk träff 2011-02-13

Effects of pergolide mesylate on transduction efficiency of PEP-1-catalase protein.

Sohn EJ, Kim DW, Kim YN, Kim SM, Lim SS, Kang TC, Kwon HY, Kim DS, Cho SW, Han KH, Park J, Eum WS, Hwang HS, Choi SY.

Biochem Biophys Res Commun · research support, non-u.s. gov't; journal article · DOI 10.1016/j.bbrc.2011.02.038

Bibliografisk träff 2010-08-09

Multitemperature stability and degradation characteristics of pergolide mesylate oral liquid.

Shank BR, Ofner CM.

J Pharm Pract · journal article · DOI 10.1177/0897190010375851

Bibliografisk träff 2010-01-01

Single-dose oral pharmacokinetics of pergolide mesylate in healthy adult mares.

Gehring R, Beard L, Wright A, Coetzee J, Havel J, Apley M.

Vet Ther · research support, non-u.s. gov't; journal article

Bibliografisk träff 2009-10-01

Effects of pergolide mesilate on metallothionein mRNAs expression in a mouse model for Parkinson disease.

Ono S, Hirai K, Tokuda E.

Biol Pharm Bull · journal article · DOI 10.1248/bpb.32.1813

Bibliografisk träff 2009-05-01

Stability of pergolide mesylate oral liquid at room temerature.

Shank BR, Ofner CM.

Int J Pharm Compd · journal article

Bibliografisk träff 2009-02-01

Effects of compounding and storage conditions on stability of pergolide mesylate.

Davis JL, Kirk LM, Davidson GS, Papich MG.

J Am Vet Med Assoc · research support, non-u.s. gov't; journal article · DOI 10.2460/javma.234.3.385

Bibliografisk träff 2004-09-01

Influence of the therapy with pergolide mesylate plus L-DOPA and with L-DOPA alone on serum cGMP level in PD patients.

Chalimoniuk M, Stepień A.

Pol J Pharmacol · comparative study; conference proceedings; research support, non-u.s. gov't

Bibliografisk träff 2004-09-01

Pergolide mesylate, a dopaminergic receptor agonist, applied with L-DOPA enhances serum antioxidant enzyme activity in Parkinson disease.

Chalimoniuk M, Stepień A, Strosznajder JB.

Clin Neuropharmacol · clinical trial; journal article · DOI 10.1097/01.wnf.0000145509.84389.ce

Bibliografisk träff 2004-07-01

Pergolide mesylate can improve sexual dysfunction in patients with Parkinson's disease: the results of an open, prospective, 6-month follow-up.

Pohanka M, Kanovský P, Bares M, Pulkrábek J, Rektor I.

Eur J Neurol · clinical trial; research support, non-u.s. gov't; journal article · DOI 10.1111/j.1468-1331.2004.00820.x

Bibliografisk träff 2003-09-23

Pergolide mesylate form II.

Jegorov A, Horák Z, Cejka J, Kratochvíl B, Císarová I.

Acta Crystallogr C · research support, non-u.s. gov't; journal article · DOI 10.1107/s0108270103017499

Bibliografisk träff 2002-09-01

[Cutaneous vasculitis during pergolide mesylate treatment].

Serratrice J, Granel B, Disdier P, Weiller PJ, Alcaraz P, Azulay JP, Jean-Pastor MJ.

Rev Med Interne · letter; case reports · DOI 10.1016/s0248-8663(02)00680-x

Bibliografisk träff 2001-02-01

[Sleep attacks and pergolide mesylate].

García Ruiz PJ, Hernández J, Cantarero S, Fanjul S.

Neurologia · letter; case reports

Bibliografisk träff 2001-01-01

Pergolide mesilate may improve fatigue in patients with Parkinson's disease.

Abe K, Takanashi M, Yanagihara T, Sakoda S.

Behav Neurol · clinical trial; research-article; journal article · DOI 10.1155/2002/473140

Bibliografisk träff 1999-01-01

Pergolide mesylate for cocaine abuse: a controlled preliminary trial.

Levin FR, McDowell D, Evans SM, Brooks D, Spano C, Nunes EV.

Am J Addict · comparative study; clinical trial; research support, u.s. gov't, p.h.s.; randomized controlled trial; journal article · DOI 10.1080/105504999305929

Bibliografisk träff 1995-04-01

Psychoactive properties of pergolide mesylate.

Wilcox JA.

J Psychoactive Drugs · journal article; case reports · DOI 10.1080/02791072.1995.10471689

Bibliografisk träff 1995-01-01

Pergolide mesylate in Parkinson's disease treatment.

Pezzoli G, Canesi M, Pesenti A, Mariani CB.

J Neural Transm Suppl · review; journal article

Bibliografisk träff 1982-10-01

Pergolide mesylate and idiopathic Parkinson disease.

Tanner CM, Goetz CG, Glantz RH, Glatt SL, Klawans HL.

Neurology · research support, u.s. gov't, p.h.s.; journal article · DOI 10.1212/wnl.32.10.1175